UNSPSC 51332401: Pentabamate

This classification denotes an antipsychotic agent with the molecular formula C8H16N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8871ZB4UGC, chemically known as 1,2,3-trimethyltrimethylenedicarbamate but generally known as pentabamate, which bears US NIH Compound Identifier 3047822. European Medicines Agency schedules Pentabamate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09674MIG.

UNSPSC 51332401 Pentabamate is a Commodity code that in practice captures pharmaceutical and medical supply procurement by state and local health agencies, though the recent opportunities show limited direct pentabamate activity and instead reflect broader pharmaceutical and opioid-response product sourcing. State and local health departments, cooperative purchasing alliances, and county community health systems are the primary issuing bodies, with health and human services commissions managing larger multi-jurisdictional pharmaceutical programs. The scope of work encompasses procurement of generic pharmaceuticals, over-the-counter products, naloxone, and drug deactivation systems acquired through competitive bidding, RFPs, and RFIs to support public health initiatives, employee health plans, and community health building operations.

Recent activity spans Florida, Texas, and Minnesota through multi-state cooperative vehicles. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, gathering market intelligence on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements, with no award value disclosed at the preliminary stage. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administered by the Minnesota Department of Administration issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities and Oregon, with proposals due March 26, 2026, awarded vendors required to be available by May 1, 2026, and contracts effective July 1, 2026; MMCAP reserves multi-award authority and requires vendors to maintain relationships with authorized wholesalers including AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC.